Global Cancer Vaccine Market & Clinical Trial Insight

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

The concept of vaccines dates back to1881, when Edward Jenner developed the first vaccine to treat small pox. Since then many technological advancements have been made, in modern times, vaccines have been developed as a new therapeutic for prevention and eradication of cancer. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity. Researchers came up with the idea of cancer vaccines to alleviate patients suffering from cancer.

Conventionally, vaccines were used for the prevention of contagious diseases, they work by boosting the immune response against the pathogens. Analogously, cancer vaccines work by activating the immune system to attack on cancer cells. Researchers developed cancer vaccines to alleviate patients suffering from cancer. With the technological advances, cancer vaccines have been developed as a new therapeutic for cancer prevention and eradication. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:

Global Cancer Market Overview
Emergence of Personalized Cancer Vaccines
Platforms for Cancer Vaccines Delivery
Mechanism of Cancer Vaccines
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
Marketed Cancer Vaccines: 15 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing

1. Introduction to Cancer Vaacines

2. Mechanism of Cancer Vaccines

2.1 Idiotype Cancer Vaccine Mechanism

2.2 Cellular Cancer Vaccines Mechanism

2.3 Ganglioside Antigens based Cancer Vaccines Mechanism

2.4 Peptide Cancer Vaccine Mechanism

2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Therapy for Cancer Vaccines

4. Global Cancer Vaccines Market Overview

4.1 Current Market Scenario

4.2 Global Cancer Vaccine Drug Pipeline by Indication

5. Emergence of Personalized Cancer Vaccines

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics

7.1 Favorable Market Parameters

7.1.1 Pottential Demand for Cancer Vaccines

7.1.2 Public Cancer Vaccination Program

7.1.3 Advancements in Development Technology

7.1.4 Personalized Cancer Vaccines

7.1.5 Myriad of Demographs for Cancer Vaccine Development

7.2 Commercialization Challenges

8. Global Cancer Vaccine Market Future Outlook

9. Bladder Cancer Vaccine Clinical Pipeline Insight by Company & Phase

9.1 Phase-II

10. Blood Cancer Vaccine Clinical Pipeline Insight by Company & Phase

10.1 Research till Preregistration

11. Brain Cancer Vaccine Clinical Pipeline Insight by Company & Phase

11.1 Preclinical Till Phase-III

12. Breast Cancer Vaccine Clinical Pipeline Insight by Company & Phase

12.1 Preclinical till Phase-III

13. Cancer Vaccine Clinical Pipeline Insight by Company & Phase

13.1 Research till Phase-II

14. Cervical Cancer Vaccine Clinical Pipeline Insight by Company & Phase

14.1 Phase-II

15. Colorectal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

15.1 Preclinical till Preregistration

16. Head and Neck Cancer Vaccine Clinical Pipeline Insight by Company & Phase

16.1 Preclinical till Phase-I/II

17. Liver Cancer Vaccine Clinical Pipeline Insight by Company & Phase

17.1 Phase-I till Phase-II

18. Lung Cancer Vaccine Clinical Pipeline Insight by Company & Phase

18.1 Preclinical till Phase-III

19. Oesophageal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

19.1 Phase-III

20. Ovarian Cancer Vaccine Clinical Pipeline Insight by Company & Phase

20.1 Preclinical till Phase-III

21. Pancreatic Cancer Vaccine Clinical Pipeline Insight by Company & Phase

21.1 Reseach till Phase-III

22. Prostate Cancer Vaccine Clinical Pipeline Insight by Company & Phase

22.1 Preclinical till Phase-III

23. Renal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

23.1 Phase-I till Phase-III

24. Sarcoma Vaccine Clinical Pipeline Insight by Company & Phase

24.1 Phase-II

25. Skin Cancer Vaccine Clinical Pipeline Insight by Company & Phase

25.1 Preclinical till Phase-III

26. Solid Tumours Vaccine Clinical Pipeline Insight by Company & Phase

26.1 Preclinical till Phase-II

27. Multiple Cancer Vaccine Clinical Pipeline Insight by Company & Phase

27.1 Preclinical till Phase-III

28. Marketed Cancer Vaccine Clinical Insight by Company & Indication

28.1 Bladder Cancer

28.1.1 BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®)

28.1.2 Bladder Cancer Vaccine (PACIS®)

28.1.3 Bladder Cancer Vaccine - Organon Teknika

28.2 Cervical Cancer

28.2.1 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

28.3 Lung Cancer

28.3.1 BV NSCLC 001

28.3.2 Cadi 05 (Immuvac® & Mycidac-C™)

28.3.3 Racotumomab (Vaxira®)

28.4 Pancreatic Cancer

28.4.1 Tertomotide (LucaVax)

28.5 Prostate Cancer

28.5.1 Sipuleucel-T (Provenge®)

28.6 Renal Cancer

28.6.1 Renal Cancer Vaccine (Reniale®)

28.6.2 Vitespen (Oncophage®)

28.7 Skin Cancer

28.7.1 Melanoma Vaccine (MVax®)

28.7.2 Melanoma Vaccine (Melacine®)

28.8 Multiple Cancer

28.8.1 Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)

28.8.2 Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

29. Discontinued & Suspended Cancer Vaccine Drug Clinical Pipeline Insight

29.1 No Development Reported

29.2 Discontinued

29.3 Suspended

30. FDA Regulatory Framework for Cancer Vaccines Development & Marketing

30.1 Considerations for both Early and Late Phase Clinical Trials

30.1.1 Patient Population

30.1.2 Monitoring the Immune Response

30.1.3 Biomarkers as Evidence Of Efficacy

30.1.4 Adjuvants Used To Stimulate Immune Response

30.1.5 Multi-Antigen Vaccines

30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines

30.1.7 Concomitant and Subsequent Therapies

30.2 Considerations for Early Phase Clinical Trials

30.2.1 Starting Dose and Dosing Schedule

30.2.2 Booster and Maintenance Therapy

30.2.3 Dose Escalation

30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development

30.3 Considerations for Late Phase Clinical Trials

30.3.1 Safety Profile from Early Phase Clinical Trials

30.3.2 Endpoints

30.3.3 Statistical Issues

30.3.4 Control Issues

30.3.5 Delayed Vaccine Effect

30.3.6 Autologous Vaccine Trials

30.3.7 Accelerated Approval Regulations

31. Competitive Landscape: Business Overview & Product Pipeline

31.1 Advaxis

31.2 AVAX Technologies

31.3 Celldex Therapeutics

31.4 Dendreon Corporation

31.5 Galena Biopharma

31.6 GlaxoSmithKline

31.7 ImmunoCellular Therapeutics

31.8 ImmunoGen

31.9 Inovio Pharmaceuticals

31.10 KAEL-GemVax

31.11 Liponova

31.12 MedImmune

31.13 Merck

31.14 NeoStem Oncology

31.15 NewLink Genetics

31.16 Northwest Biotherapeutics

31.17 Novartis

31.18 Peregrine Pharmaceuticals

31.19 Recombio

31.20 Roche

31.21 Sanofi

31.22 Seattle Genetics

31.23 Valeant Pharmaceuticals

Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020

Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020

Figure 4-3: Examples of Commercially Available Cancer Vaccines

Figure 4-4: Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-5: Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-6: Bladder Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-7: Bladder Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-8: Blood Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-9: Blood Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-10: Brain Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-11: Brain Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-12: Breast Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-13: Breast Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-14: Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-15: Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-16: Cervical Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-17: Cervical Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-18: Colorecta Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-19: Colorecta Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-20: Head & Neck Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-21: Head & Neck Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-22: Liver Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-23: Liver Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-24: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-25: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-26: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-27: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-28: Pancreatic Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-29: Pancreatic Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-30: Prostate Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-31: Prostate Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-32: Renal Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-33: Renal Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-34: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-35: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-36: Solid Tumour Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-37: Solid Tumour Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-38: Multiple Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-39: Multiple Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-40: No Development Reported Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-41: No Development Reported Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-42: Discontinued Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-43: Discontinued Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 4-44: Suspended Cancer Vaccine Drug Pipeline by Phase (%), 2015

Figure 4-45: Suspended Cancer Vaccine Drug Pipeline by Phase (Number), 2015

Figure 5-1: Overview of Personalized Cancer Vaccines Development

Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine

Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine

Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV

Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines

Figure 31-1: Advaxis Clinical Pipeline

Figure 31-2: Celldex Therapeutics Clinical Pipeline

Figure 31-3: Galena Biopharma Clinical Pipeline

Figure 31-4: ImmunoCellular Therapeutics Clinical Pipeline

Figure 31-5: ImmunoGen Clinical Pipeline

Figure 31-6: Inovio Pharmaceuticals Clinical Pipeline

Figure 31-7: KAEL-Gemvax Clinical Pipeline

Figure 31-8: NewLink Genetics Corporation Clinical Pipeline

Figure 31-9: Northwest Biotherapeutics Clinical Pipeline

Figure 31-10: Peregrine Pharmaceuticals Clinical Pipeline

Figure 31-11: Seattle Genetics Clinical Pipeline

Table 5-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Cancer Vaccine Market & Clinical Trial Insight

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected